Koren-Michowitz M - Search Results

1

Myeloid sarcoma: current approach and therapeutic options.

Avni B, Koren-Michowitz M. Avni B, et al. Ther Adv Hematol. 2011 Oct;2(5):309-16. doi: 10.1177/2040620711410774. Ther Adv Hematol. 2011. PMID: 23556098 Free PMC article.

2

Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study.

Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S, Golik A. Koren-Michowitz M, et al. Pharmacoepidemiol Drug Saf. 2004 May;13(5):299-302. doi: 10.1002/pds.881. Pharmacoepidemiol Drug Saf. 2004. PMID: 15133781 Clinical Trial.

3

Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.

Chan D, Koren-Michowitz M. Chan D, et al. Ther Adv Hematol. 2011 Apr;2(2):61-71. doi: 10.1177/2040620711401646. Ther Adv Hematol. 2011. PMID: 23556077 Free PMC article.

4

Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia.

Hardan I, Stanevsky A, Volchek Y, Tohami T, Amariglio N, Trakhtenbrot L, Koren-Michowitz M, Shimoni A, Nagler A. Hardan I, et al. Cytokine. 2012 Feb;57(2):290-3. doi: 10.1016/j.cyto.2011.11.018. Epub 2011 Dec 13. Cytokine. 2012. PMID: 22169779 Clinical Trial.

5

Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.

Koren-Michowitz M, Maayan H, Apel A, Shem-Tov N, Yerushalmi R, Volchek Y, Avigdor A, Shimoni A, Nagler A. Koren-Michowitz M, et al. Ann Hematol. 2015 Mar;94(3):375-8. doi: 10.1007/s00277-014-2229-3. Epub 2014 Oct 14. Ann Hematol. 2015. PMID: 25307457

6

Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.

Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A. Koren-Michowitz M, et al. Cancer. 2010 Oct 1;116(19):4564-72. doi: 10.1002/cncr.25351. Cancer. 2010. PMID: 20572041 Free article.

7

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC.

Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, Shimoni A, Nagler A. Koren-Michowitz M, et al. Hematol Oncol. 2012 Dec;30(4):200-5. doi: 10.1002/hon.2005. Epub 2012 Jan 12. Hematol Oncol. 2012. PMID: 22241698

8

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shimoni A, Volchek Y, Koren-Michowitz M, Varda-Bloom N, Somech R, Shem-Tov N, Yerushalmi R, Nagler A. Shimoni A, et al. Cancer. 2015 Mar 15;121(6):863-71. doi: 10.1002/cncr.29141. Epub 2014 Nov 11. Cancer. 2015. PMID: 25387866 Free article. Clinical Trial.

9

Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.

Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N. Koren-Michowitz M, et al. Am J Hematol. 2005 Mar;78(3):203-6. doi: 10.1002/ajh.20310. Am J Hematol. 2005. PMID: 15726604 Free article.

10

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.

Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, Canaani J, Zektser M, Duek A, Stemer G, Hellman I, Basood M, Frisch A, Leibovitch C, Koren-Michowitz M. Apel A, et al. Am J Hematol. 2021 Jul 1;96(7):790-795. doi: 10.1002/ajh.26190. Epub 2021 Apr 29. Am J Hematol. 2021. PMID: 33836555 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page